Abstract
To investigate the diagnostic value of cell-free DNA (cfDNA) and long fragment DNA in breast cancer patients.Female patients with breast cancer (n = 80) were recruited over one year for this study, and served as an observation group. The control group consisted of 50 normal, healthy females. Plasma levels of cfDNA and long fragment DNA were determined a day before treatment, 7 days after treatment, and on the 20th day of treatment. The levels of cfDNA and long fragment DNA in breast cancer patients before treatment were significantly higher than those of the control group (p<0.05). Patients cfDNA and long fragment DNA levels 7 days after treatment were not significantly different from the corresponding values at 1 day before treatment (p>0.05), but they decreased significantly on the 20th day of treatment, when compared with levels before treatment (p<0.05). Before treatment, the optimal cut-off point for cfDNA in patients' peripheral blood, sensitivity, specificity and accuracy were 12.25ng/mL, 79.12%, 86.15%, and 73.32%, respectively. The area under the ROC curve (AUC) was 0.865 (95% CI = 0.754-0.903). Close monitoring of cfDNA levels in peripheral blood of breast cancer patients in real-time can be used for early diagnosis of the disease.
Highlights
Breast cancer, the most common malignancy in women, accounts for 25.1% of all cancer cases worldwide, and it seriously affects the quality of life of women
The present study investigated the diagnostic value of cell-free DNA (cfDNA) and long fragment DNA in breast cancer patients
Circulating free DNA is degraded DNA fragments released to the blood plasma
Summary
The most common malignancy in women, accounts for 25.1% of all cancer cases worldwide, and it seriously affects the quality of life of women. The incidence of breast cancer is higher in developed countries, while relative mortality is higher in less developed countries. The education of women has been suggested for the early detection and treatment of breast cancer. Advancements in medical technology have impacted positively on the diagnosis and treatment of breast cancer [4]. This has greatly reduced mortality from breast cancer, the disease remains the leading cause of death in women [4]. Diagnosis and treatment are key to the effective management of the disease This has necessitated the search for novel biomarkers that can effectively diagnose breast cancer and offer a good prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
